Company intelligence / Profile preview

USSL 22

Ownership: Private
Development stage: Other

Overview

USSL 22 is a biotechnology company focused on the development of advanced drug delivery systems using ultrasmall silica nanoparticles. The company's technology platform is designed to enhance the precision and efficacy of therapeutic agents, particularly in the field of oncology. By leveraging the unique properties of silica-based nanocarriers, USSL 22 aims to improve the pharmacokinetic profiles and targeted delivery of small molecule drugs. The company is currently in the pre-clinical stage, optimizing its lead candidates for future clinical evaluation.

Therapeutic areas: Oncology
Modalities: NanoparticleSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on USSL 22.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on USSL 22.

Explore the full profile